Press Releases

COLUMBUS, Ohio, Nov. 20, 2019 /PRNewswire/ -- A workforce readiness program supporting the Franklinton and Hilltop communities is demonstrating early success, with seven participants securing quality careers within months of completing training.

SOUTH SAN FRANCISCO, Calif., Nov. 20,  2019 /PRNewswire/ -- Forensic scientists now have access to the

MILWAUKEE, Nov. 20, 2019 /PRNewswire/ -- In recognition of his distinguished career working as a senior investigator at Versiti Blood Research Institute for nearly 50 years,

MONMOUTH JUNCTION, N.J., Nov. 20, 2019 /PRNewswire/ -- DiamiR, a developer of innovative blood-based diagnostic tests for neurodegenerative and other diseases, announced today a $492,000 award in support of the project entitled "Circulating brain-enriched microRNAs as peripheral biomarkers of neurodegeneration." The award will accelerate the

PORTLAND, Ore., Nov. 20, 2019 /PRNewswire/ -- Today, Social CBD (www.thesocialcbd.com) announced a health and wellness-focused partnership with the reigning SLS World Cham

TORONTO and HOUSTON, Nov. 20, 2019 /PRNewswire/ - Medicenna Therapeutics Corp.  ("Medicenna" or "the Company") (TSX: MDNA, OTCQB: MDNAF), a clinical stage Immuno-Oncology company, today announced that it will host a Key Opinion Leader (KOL) call and webcast for the investment community on Monday,

-- Third quarter revenue of $26.8 million, an increase of 53% from $17.6 million in the second quarter and compared with $1.8 million in the third quarter of 2018-- Improved gross profit margin to 26.1% from 12.3% in the second quarter-- Increasing strategic focus on la

SAN DIEGO and VANCOUVER, British Columbia, Nov. 20, 2019 /PRNewswire/ -- Phoenix Molecular Designs (PhoenixMD), a clinical stage biotechnology company developing precise cancer the

SEATTLE, Nov. 20, 2019 /PRNewswire/ -- Athira Pharma, Inc., a clinical-stage company developing first-in-class therapies focused on regeneration of neuronal damage in CNS diseases to restore function, today announced that data from the completed Phase 1 clinical trial of its lead development candidate, NDX-1017, a novel small molecule therapeutic for cognitive enhancemen

SAN MATEO, Calif., Nov. 20, 2019 /PRNewswire/ -- Apttus, the Middle Office leader, announced that B. Braun, a leader in medical products and services in the healthcare industry, has implemented Apttus Contract